Simple blood fibrosis tests reduce unnecessary referrals for specialized evaluations of liver fibrosis in NAFLD and ALD patients.
Alanine Transaminase
/ blood
Aspartate Aminotransferases
/ blood
Biomarkers
/ blood
Female
Health Services Misuse
/ prevention & control
Humans
Liver Cirrhosis
/ blood
Liver Diseases, Alcoholic
/ blood
Male
Middle Aged
Non-alcoholic Fatty Liver Disease
/ blood
Platelet Count
Pregnancy-Associated alpha 2-Macroglobulins
/ analysis
Prothrombin Time
Referral and Consultation
/ statistics & numerical data
Retrospective Studies
gamma-Glutamyltransferase
/ blood
Care pathway
FIB4
Liver fibrosis
Referral
eLIFT
Journal
Clinics and research in hepatology and gastroenterology
ISSN: 2210-741X
Titre abrégé: Clin Res Hepatol Gastroenterol
Pays: France
ID NLM: 101553659
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
24
04
2019
revised:
28
06
2019
accepted:
08
07
2019
pubmed:
20
8
2019
medline:
9
9
2021
entrez:
19
8
2019
Statut:
ppublish
Résumé
Liver fibrosis evaluation is mandatory in non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD) to decide the patient management. Patients with these diseases are usually under the care of non-liver specialists who refer them to specialized centers where the most accurate fibrosis tests are available. We aimed to evaluate whether simple blood fibrosis tests available to all physicians help to reduce the rate of unnecessary referral of NAFLD and ALD patients without advanced fibrosis. NAFLD and/or ALD patients newly referred to our center for a non-invasive evaluation of liver fibrosis were retrospectively included. The FibroMeter 558 patients were included (NAFLD: 283, ALD: 156, mixed NAFLD+ALD: 119). FM The use of eLIFT by non-liver specialists for NAFLD and ALD patients can improve the relevance of referrals for specialized evaluation of liver fibrosis.
Sections du résumé
BACKGROUND
Liver fibrosis evaluation is mandatory in non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD) to decide the patient management. Patients with these diseases are usually under the care of non-liver specialists who refer them to specialized centers where the most accurate fibrosis tests are available. We aimed to evaluate whether simple blood fibrosis tests available to all physicians help to reduce the rate of unnecessary referral of NAFLD and ALD patients without advanced fibrosis.
METHODS
NAFLD and/or ALD patients newly referred to our center for a non-invasive evaluation of liver fibrosis were retrospectively included. The FibroMeter
RESULTS
558 patients were included (NAFLD: 283, ALD: 156, mixed NAFLD+ALD: 119). FM
CONCLUSION
The use of eLIFT by non-liver specialists for NAFLD and ALD patients can improve the relevance of referrals for specialized evaluation of liver fibrosis.
Identifiants
pubmed: 31422033
pii: S2210-7401(19)30175-5
doi: 10.1016/j.clinre.2019.07.010
pii:
doi:
Substances chimiques
Biomarkers
0
Pregnancy-Associated alpha 2-Macroglobulins
0
gamma-Glutamyltransferase
EC 2.3.2.2
Aspartate Aminotransferases
EC 2.6.1.1
Alanine Transaminase
EC 2.6.1.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
349-355Informations de copyright
Copyright © 2019 Elsevier Masson SAS. All rights reserved.